Academia

Two posters presented at AMCP Nexus 2021 analyzed the costs of treating cytokine release syndrome and neurological events, 2 common adverse events (AEs) of chimeric antigen receptor (CAR) T-cell therapy.

Risankizumab, a biologic, is used for psoriasis, but whether it can improve asthma control has been unclear.

The authors said long-term trends in Parkinson disease were previously unknown and that the findings are important to determining national health care priorities.

Researchers hope that the benefits seen in a new protocol for deep brain stimulation (DBS) in Parkinsonian mice will extend to humans.

Mortality and liver-related complications increased with fibrosis stage in patients with nonalcoholic fatty liver disease (NAFLD).

A review of current molecular and electrophysiological biomarkers in spinal muscular atrophy (SMA) concluded that more exploration is necessary to find noninvasive, yet accurate, measures of disease progression and therapy response.

The benefit of real-world evidence is that it provides more data on subpopulations and diverse populations, said Christina Barrington, vice president of pharmacy programs at Priority Health.

There are several reasons as to why precision therapeutics have not taken off for chronic obstructive pulmonary disease (COPD) in the same way that they have for other diseases, said Don Sin, MD, FRCP, MPH, a professor of respiratory medicine at the University of British Columbia and head of the Centre of Heart Lung Innovation, St. Paul’s Hospital.

Dosing from pivotal phase 3 trials of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) is not optimal for real-world patients who experience different efficacy and adverse events (AEs).

Increasing knowledge of mutations and signaling proteins in diffuse large B-cell lymphoma (DLBCL) offer prognostic and therapeutic advantages, according to a review of recent findings.

In the opening sessions at the Patient-Centered Oncology Care® conference, held September 23-24 both virtually and in Nashville, Tennessee, speakers focused on addressing disparities by getting involved and engaged with the community.

At the 10th anniversary meeting of Patient-Centered Oncology Care®, sessions will cover reducing disparities in cancer care, bringing clinical trials closer to the community, and expanding the scope of what the term "precision medicine" means in cancer care.

The fallout from COVID-19 has spotlighted the limitations of US mental health care, prompting the question if alternative treatments—like psychedelics—could help address current and impending crises.

Investigators examined medical records spanning 3 decades to look at the effect of poorly differentiated tumor size on outcomes in survival in hepatocellular carcinoma (HCC).

Increasing air pollution and climate change have an impact on respiratory health and mortality, explained speakers in 2 sessions on the environment and respiratory diseases at the European Respiratory Society International Congress 2021.

Health care and research need to do a better job of taking into account sex and gender differences that can affect disease, healthy behaviors, and care delivery, according to speakers at the European Respiratory Society International Congress 2021.

On this episode of Managed Care Cast, we speak with one of the authors of a recent book looking at the erosion of trust in health care, the factors that influence trust, and what can be done to restore trust.

The 5-year update could help solidify the role of sodium glucose co-transporter 2 (SGLT2) inhibitors in treating heart failure, years after the first evidence of their effectiveness emerged.

Researchers conducted a literature survey about chronic cough symptoms to create a patient-reported outcome measurement (PROM) tool in order to measure cough severity.

Treatment-related modifications have resulted in improved long-term outcomes for all adolescent and young adult (AYA) survivors of Hodgkin lymphoma, but new research highlights that racial, ethnic, and socioeconomic status disparities persist in the long term.

Patients may find a placebo effect beneficial, but it causes issues in a clinical trial and makes it difficult to understand the efficacy of a pharmacological agent, said Ron Eccles, BSc, PhD, DSc, emeritus professor at Cardiff University.

Dynamic measurable residual disease (MRD) can be used to optimize postremission treatment for young patients with acute myeloid leukemia (AML).

A new treatment using human immune cells can prevent infections in patients with leukemia who have a weakened immune system due to treatment for their disease.

The nationwide, population-based study analyzed data on over 1900 patients with primary myelofibrosis (pMF), comparing rates of survival from 2001-2010 with 2011-2018.

In a recent review, researchers describe what is currently known about allogenic hemopoietic stem cell transplant (HSCT) for myelofibrosis.